Literature DB >> 21594898

Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up.

Ping-Lei Pan, He-Han Tang, Qin Chen, Wei Song, Hui-Fang Shang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594898     DOI: 10.1002/mds.23797

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  6 in total

Review 1.  Aceruloplasminaemia: a rare but important cause of iron overload.

Authors:  Adam Doyle; Ferry Rusli; Prithi Bhathal
Journal:  BMJ Case Rep       Date:  2015-05-14

2.  Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment.

Authors:  L Poli; A Alberici; P Buzzi; E Marchina; A Lanari; C Arosio; A Ciccone; F Semeraro; R Gasparotti; A Padovani; Barbara Borroni
Journal:  Neurol Sci       Date:  2016-11-05       Impact factor: 3.307

3.  Off-resonance saturation as an MRI method to quantify mineral- iron in the post-mortem brain.

Authors:  Lucia Bossoni; Ingrid Hegeman-Kleinn; Sjoerd G van Duinen; Marjolein Bulk; Lena H P Vroegindeweij; Janneke G Langendonk; Lydiane Hirschler; Andrew Webb; Louise van der Weerd
Journal:  Magn Reson Med       Date:  2021-10-15       Impact factor: 3.737

Review 4.  Neurodegeneration with brain iron accumulation: diagnosis and management.

Authors:  Penelope Hogarth
Journal:  J Mov Disord       Date:  2015-01-13

Review 5.  Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.

Authors:  Vassilena Iankova; Ivan Karin; Thomas Klopstock; Susanne A Schneider
Journal:  Front Neurol       Date:  2021-04-15       Impact factor: 4.003

6.  Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.

Authors:  Lena H P Vroegindeweij; Agnita J W Boon; J H Paul Wilson; Janneke G Langendonk
Journal:  Orphanet J Rare Dis       Date:  2020-04-25       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.